EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Neal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto, Christopher M Pieczonka, Gabriel P Haas, Choung-Soo Kim, Miguel Ramirez-Backhaus, Antti Rannikko, Matko Kalac, Swetha Sridharan und 8 weitere

New England Journal of Medicine · 05.02.2026 · 394 (6) · 563-575

DOI: 10.1056/nejmoa2510310 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 05.02.2026. Verfasst von Neal D Shore und 19 weiteren Autor:innen. Beteiligte Einrichtung: START Carolinas, Myrtle Beach, SC. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leuprolide, Neoplasm Recurrence, Local, Phenylthiohydantoin. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Pfizer, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLeuprolideNeoplasm Recurrence, LocalPhenylthiohydantoinProstatic NeoplasmsAgedAged, 80 and overHumansMaleMiddle AgedAntineoplastic Agents, HormonalBenzamidesKaplan-Meier EstimateNitrilesProgression-Free SurvivalProstate-Specific AntigenTime Factors

Substanzen

Antineoplastic Agents, HormonalBenzamidesenzalutamideLeuprolideNitrilesPhenylthiohydantoinProstate-Specific Antigen

Autor:innen und Institutionen

  • START Carolinas, Myrtle Beach, SC.
  • Division of Urologic Oncology, Erasto Gaertner Hospital, Curitiba, Brazil.
  • Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
  • Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
  • Southern Alberta Institute of Urology, University of Calgary, Calgary, Canada.
  • Clinical Research, U.S. Urology Partners and Associated Medical Professionals of New York, Syracuse.

ORCID-Profile: Henry H Woo, Stephen J Freedland

Förderung

  • Pfizer
  • Astellas Pharma

Zitieren

APA

Shore, N. D., Luz, M. A., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C. S., Ramirez-Backhaus, M., Rannikko, A., Kalac, M., Sridharan, S., Rosales, M., Tang, Y., Tutrone, R. F., Venugopal, B., Villers, A., Woo, H. H., Wang, F., & Freedland, S. J. (2026). Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine, 394(6), 563-575. https://doi.org/10.1056/nejmoa2510310

Vancouver

Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 2026;394(6):563-575. doi:10.1056/nejmoa2510310

BibTeX
@article{Shore2026,
  author = {Shore, Neal D and Luz, Murilo de Almeida and De Giorgi, Ugo and Gleave, Martin and Gotto, Geoffrey T and Pieczonka, Christopher M and Haas, Gabriel P and Kim, Choung-Soo and Ramirez-Backhaus, Miguel and Rannikko, Antti and Kalac, Matko and Sridharan, Swetha and Rosales, Matt and Tang, Yiyun and Tutrone, Ronald F and Venugopal, Balaji and Villers, Arnauld and Woo, Henry H and Wang, Fong and Freedland, Stephen J},
  title = {Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {6},
  pages = {563--575},
  doi = {10.1056/nejmoa2510310}
}
Kostenlos starten →